FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

MAHONEY DAVID L 		2. Issuer Name and Ticker or Trading Symbol

Adamas Pharmaceuticals Inc [ ADMS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O ADAMAS PHARMACEUTICALS, INC., 2200 POWELL ST, STE 220 		3. Date of Earliest Transaction (MM/DD/YYYY)

4/15/2014
(Street)

EMERYVILLE, CA 94608
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   4/15/2014     C    13147   A   (1) (2) 23821   D    
Common Stock   4/15/2014     C    2628   A   (2) 2628   I   David L. Mahoney + Winnifred C. Ellis 1998 Family Trust  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series AA Convertible Preferred Stock     (2) 4/15/2014     C         13144      (2)   (3) Common Stock   13144   $0.00   0   D    
Series AA Convertible Preferred Stock     (2) 4/15/2014     C         2628      (2)   (3) Common Stock   2628   $0.00   0   I   David L. Mahoney + Winnifred C. Ellis 1998 Family Trust  
Series AA-1 Convertible Preferred Stock     (1) 4/15/2014     C         3      (1)   (3) Common Stock   3   $0.00   0   D    
Stock Option (Right to Buy)   $1.755                      (4) 9/30/2019   Common Stock   33332     33332   D    
Stock Option (Right to Buy)   $0.665                      (5) 11/16/2021   Common Stock   48000     48000   D    
Stock Option (Right to Buy)   $8.995                      (6) 2/2/2024   Common Stock   30000     30000   D    

Explanation of Responses:
( 1)  Upon the closing of the Issuer's initial public offering, each 1000 shares of Series AA-1 Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
( 2)  Upon the closing of the Issuer's initial public offering, each share of Series AA Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
( 3)  The shares do not have an expiration date.
( 4)  The Option shares shall vest as follows: 1/4th of the shares subject to such option shall vest each year after June 1, 2009, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2007 Stock Plan) as of each such date. The Option shares are subject to an early exercise right and may be exercised in full prior to vesting.
( 5)  The Option shares shall vest as follows: one-fifth (1/5th) of the shares vest one year after June 30, 2011; the balance of the shares vest in a series of forty-eight (48) successive equal monthly installments measured from the first anniversary of June 30, 2011, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2007 Stock Plan) as of each such date. The Option shares are subject to an early exercise right and may be exercised in full prior to vesting.
( 6)  The Option shares shall vest as follows: 1/3rd of the shares subject to such option shall vest each year after February 2, 2014, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2007 Stock Plan) as of each such date. The Option shares are subject to an early exercise right and may be exercised in full prior to vesting.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
MAHONEY DAVID L
C/O ADAMAS PHARMACEUTICALS, INC.
2200 POWELL ST, STE 220
EMERYVILLE, CA 94608 		X



Signatures
/s/Danielle Naftulin, as Attorney-in-Fact 4/15/2014
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jul 2024 to Aug 2024 Click Here for more Adamas Pharmaceuticals Charts.
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Aug 2023 to Aug 2024 Click Here for more Adamas Pharmaceuticals Charts.